Illumina, Inc.'s acquisition of GRAIL, Inc. was disastrous and created all kinds of problems, but the company is refocusing on its profitable core gene sequencing business. ILMN's revenue growth ...

In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

While Illumina completed the takeover of Grail last September, it has maintained the business as a separate subsidiary company while it waits for the outcome of antitrust reviews in the US and Europe.

Grail was officially spun off from Illumina in June 2024 as the European Commission prohibited Illumina's acquisition of Grail in 2022. Grail's sole product is the Galleri Test, which is a multi ...

According to the decision of the EU's Court of Justice in Luxembourg, the European Commission had no right to block the acquisition of Grail Inc. by Illumina Inc. for $7 billion. This is stated in the ...

Nearly four years after pitching for Grail, Illumina finally separated the cancer blood test developer. To expand its reach in single-cell analysis and multiomics research, Illumina acquired ...

GRAIL’s business revolves around its product, Galleri. Galleri is an early cancer detection test for people over the age of 50 who are not showing symptoms. Illumina ILMN spun off the company in ...

Illumina, Inc. (NASDAQ ... due to its controversial multi-billion dollar deal to acquire cancer test maker Grail Inc (NASDAQ:GRAL). Also NORTHAMPTON, MA / ACCESSWIRE / December 16, 2024 ...

Also Read: European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine Nearly four years after pitching for Grail, Illumina finally separated the ...

Nearly four years after pitching for Grail, Illumina finally separated the cancer blood test developer. To expand its reach in single-cell analysis and multiomics research, Illumina acquired privately ...